Archives for October 1st, 2018
Novartis strikes deal with Chinese firm to make Kymriah
Custom Synthesis, Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to...
Insmed’s treatment-resistant lung disease drug gets FDA approval
Custom Synthesis, The Food and Drug Administration on Friday approved Insmed Inc’s lead drug to treat a rare, chronic lung disease, making it...
FDA halts imports from China’s Huahai after heart drug recall
Custom Synthesis, The Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients...